☆ 4.7 Review

Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Medical Laboratory Technology

Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response

Ashley Di Meo et al.

Summary: The antibody response to SARS-CoV-2 mRNA vaccines differs significantly between healthcare workers and solid organ transplant recipients. The absolute values generated from each of the assay platforms are not interchangeable, and antibody levels differ with increased time intervals between vaccine administration and blood draw as well as between the first and second dose administration.

JOURNAL OF APPLIED LABORATORY MEDICINE (2022)

Add to Collection

Review Oncology

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

Andrea Becerril-Gaitan et al.

Summary: Patients with cancer have impaired immune response to COVID-19 vaccination compared with controls, with lower seroconversion rates and higher likelihood of SARS-CoV-2 infection.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Review Hematology

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

Nico Gagelmann et al.

Summary: Vaccination against SARS-CoV-2 has shown lower antibody response in patients with hematological malignancies compared to solid cancer and healthy controls. Different types of hematological malignancies also exhibit varying outcomes. Further studies on timing, value of boosters, and long-term efficacy are warranted.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers

R. Palich et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Letter Oncology

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

J. Barriere et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Editorial Material Health Care Sciences & Services

Using preprints in evidence synthesis: Commentary on experience during the COVID-19 pandemic

Barbara Clyne et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)

Add to Collection

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Aakash Desai et al.

Summary: The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease, and it is necessary to prioritize cancer patients, including those participating in oncology clinical trials, for vaccination. Data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited, but the benefits of vaccination are likely to far outweigh the risks of adverse events.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia

Patrick Harrington et al.

Summary: This study found that most patients with CML developed antibodies and polyfunctional T-cell responses after receiving a single dose of the SARS-CoV-2 BNT162b2 vaccine, demonstrating good immunogenicity in this patient population compared to those with solid tumors or lymphoid hematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Hematology

Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms

Onima Chowdhury et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Alfredo Addeo et al.

Summary: Among cancer patients, most (94%) achieved seroconversion after receiving two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response.

CANCER CELL (2021)

Add to Collection

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Evangelos Terpos et al.

Summary: The SARS-CoV-2 vaccination provides significant protection, but cancer patients under systemic therapy show lower levels of neutralizing antibodies compared to healthy individuals, particularly those receiving Immune Checkpoint Inhibitors. This discrepancy should be taken into consideration for patients undergoing treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Madhumita Shrotri et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Moriah Bergwerk et al.

Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Amir Massarweh et al.

Summary: The study showed that 90% of patients with cancer undergoing treatment had an adequate antibody response to the BNT162b2 vaccine, although their antibody titers were significantly lower than those of healthy controls. Further research is needed to explore the clinical relevance and durability of these lower titers.

JAMA ONCOLOGY (2021)

Add to Collection

Article Nutrition & Dietetics

Coronavirus Disease 2019 (COVID-19) Meets Obesity: Strong Association between the Global Overweight Population and COVID-19 Mortality

Jingzhou Wang et al.

JOURNAL OF NUTRITION (2021)

Add to Collection

Article Immunology

Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Bhumsuk Keam et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Letter Oncology

Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City

H. Miyashita et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Vikas Mehta et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer et al.

LANCET (2020)

Add to Collection

Review Oncology

The Impact of the COVID-19 Pandemic on Cancer Patients

Osama M. Al-Quteimat et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2020)

Add to Collection

Review Hematology

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Joshua A. Hill et al.

BLOOD (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Cancer statistics, 2019

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

Add to Collection

Article Public, Environmental & Occupational Health

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season

Lisa A. Grohskopf et al.

MMWR RECOMMENDATIONS AND REPORTS (2019)

Add to Collection

Article Oncology

Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer

Rashmi Verma et al.

BREAST CANCER RESEARCH (2016)

Add to Collection

Article Medicine, General & Internal

PROSPERO's progress and activities 2012/13

Alison Booth

SYSTEMATIC REVIEWS (2013)

Add to Collection

Article Health Care Sciences & Services

GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)

Gordon H. Guyatt et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)

Add to Collection

Review Health Care Sciences & Services

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.